07 Oct 2026, 15:25 IST
Dr. Lal Path Labs Ltd.
HDFC Securities · BUY · target Rs 2,080
The report expects 17% YoY revenue growth with volume-led gains and margin expansion, naming it a strong performer.
From Pharma and Healthcare Q2FY27 Preview HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.